1. Baas, H., Schneider, E., Fischer, P.-A.: CU 32-085 versus Bromocriptin in der Kombinationstherapie beim Parkinson-Syndrom. In: Pathophysiologie, Klinik und Therapie des Parkinsonismus (Gänshirt, H., ed.), pp. 303?308. Basel-Grenzach-Wyhlen: Editiones Roche. 1983.
2. Biesemeyer, H., Ludin, H. P., Ringwald, E.: Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease. J. Neurol.230, 19?23 (1983).
3. Enz, A.: Biphasic influence of a 8-alpha-amino-ergoline, CU 32-085, on striatal dopamine synthesis and turnoverin vivo in the rat. Life Sci.29, 2227?2234 (1981).
4. Enz, A., Frick, W., Cosse, A., Nordmann, R.: Dopaminergic properties of CU 32-085 and its 1,20-N, N-bidemethylated metabolite. In: Abstracts of the 13 th CINP Congress, Jerusalem 1978, Vol. 1, A-N., p. 199. Collegium Internationale Neuro-Psychopharmacologicum (1982).
5. Enz, A., Donatsch, P., Nordmann, R.: Dopaminergic properties of mesulergine (CU 32-085) and its metabolites. J. Neural. Transm. In press (1985 a).